eISSN 2325-4416

Logo



Get your full text copy in PDF

Bio-Artificial Heart as Ultimate Treatment of End-Stage Heart Failure

Francis Edwin Smit, Pascal Maria Dohmen

(Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa)

Med Sci Monit Basic Res 2014; 20:161-163

DOI: 10.12659/MSMBR.892287


Abstract: End-stage heart failure is a major health problem, but implementation of guidelines and optimizing medical therapy for this devastating disease should decrease mortality. If optimal conservative therapy is no longer sufficient, a mechanical support system may be required as final destination therapy or as bridge-to-transplant. Since the first heart transplantation in 1967, this therapy has become the criterion standard for end-stage heart failure, but is limited due to organ shortage. Tissue engineering could help overcome this limitation and provide regeneration, remodeling, and growth potential. This so-called bio-artificial heart would be available, created by a decellularized extracellular matrix and seeded with in vitro proliferated autologous cardiovascular cells. Results of the first experimental studies have been promising, but numerous challenges must be met before this procedure will be available.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree